(Q27645411)

English

Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha

scientific article

In more languages

Statements

scholarly article

0 references

Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha (English)

0 references

Hepatitis C virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Yi Zhou

1

0 references

Ute Müh

2

0 references

Brian L Hanzelka

3

0 references

Doug J Bartels

4

0 references

Yunyi Wei

5

0 references

B Govinda Rao

6

0 references

Debra L Brennan

7

0 references

Ann M Tigges

8

0 references

Lora Swenson

9

0 references

Ann D Kwong

10

0 references

Chao Lin

11

0 references

language of work or name

0 references

publication date

3 August 2007

0 references

Journal of Biological Chemistry

0 references

282

0 references

22619-28

0 references

31

0 references

Epidemiology of hepatitis C: geographic differences and temporal trends

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610207200

21 January 2018

Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610207200

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610207200

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610207200

21 January 2018

Diagnosis, management, and treatment of hepatitis C

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610207200

21 January 2018

Proteolytic processing and membrane association of putative nonstructural proteins of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610207200

21 January 2018

Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610207200

21 January 2018

The hepatitis C virus NS3 serine proteinase and NS4A cofactor: establishment of a cell-free trans-processing assay

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610207200

21 January 2018

Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610207200

21 January 2018

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610207200

21 January 2018

Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610207200

21 January 2018

Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610207200

21 January 2018

Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610207200

21 January 2018

In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610207200

21 January 2018

Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610207200

21 January 2018

In Vitro Selection and Characterization of Hepatitis C Virus Serine Protease Variants Resistant to an Active-Site Peptide Inhibitor

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610207200

21 January 2018

In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610207200

21 January 2018

Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610207200

21 January 2018

Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610207200

21 January 2018

Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610207200

21 January 2018

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610207200

21 January 2018

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610207200

21 January 2018

Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610207200

21 January 2018

A continuous assay of hepatitis C virus protease based on resonance energy transfer depsipeptide substrates

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610207200

21 January 2018

Mechanistic role of an NS4A peptide cofactor with the truncated NS3 protease of hepatitis C virus: elucidation of the NS4A stimulatory effect via kinetic analysis and inhibitor mapping

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610207200

21 January 2018

Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610207200

21 January 2018

Inhibition of the hepatitis C virus NS3/4A protease. The crystal structures of two protease-inhibitor complexes

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610207200

21 January 2018

VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610207200

21 January 2018

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M610207200

21 January 2018

Identifiers

10.1074/JBC.M610207200

0 references

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27645411&oldid=1503813220"